A decade of disappointing clinical trial results for Alzheimer disease (AD)-modifying therapies in people suggests that treatment should be targeted at earlier stages in the disease—even before overt symptoms arise.
No takes yet. Share an insight, caveat, or question.
M. J. Friedrich (2014) studied this question.